OnKure Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 12, 2025
OKUR$3.39+6.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Six Months Ended | ||
|---|---|---|
| June 30, | ||
| 2025 | 2024 | |
| (in thousands) | ||
| Cash flows from operating activities: | ||
| Net loss | $(31,315) | $(23,675) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Share-based compensation expense | 5,653 | 1,920 |
| Depreciation and amortization | 235 | 226 |
| Amortization of right-of-use asset - operating | 189 | 73 |
| Amortization of debt issuance costs | — | 1 |
| Change in operating assets and liabilities: | ||
| Prepaid and other assets | 1,057 | (1,264) |
| Accounts payable, accrued and other liabilities | (2,876) | 5,718 |
| Lease liabilities | (262) | (101) |
| Other long-term liabilities | 40 | — |
| Net cash used in operating activities | (27,279) | (17,102) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (31) | (19) |
| Net cash used in investing activities | (31) | (19) |
| Cash flows from financing activities: | ||
| Payment of issuance costs associated with the Concurrent Financing | (37) | — |
| Payment of reverse recapitalization transaction costs | (40) | — |
| Proceeds from issuance of convertible notes payable | — | 6,000 |
| Payment of issuance costs associated with the issuance of convertible notes payable | — | (142) |
| Proceeds from the issuance of common stock in connection with equity plans | — | 20 |
| Net cash (used in) provided by financing activities | (77) | 5,878 |
| Net decrease in cash and cash equivalents | (27,387) | (11,243) |
| Cash and cash equivalents, beginning of period | 110,761 | 29,876 |
| Cash and cash equivalents, end of period | $83,374 | $18,633 |
| Supplemental cash flow information: | ||
| Interest paid | $— | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.